Mohamed Elkasaby, MD
Neurology · Cleveland, OHNPI 1194374256
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $50,565 of the $62,050 with a category attached, or 81.5%. Lilly USA, LLC accounts for 88.1% of it on its own, with 18 other manufacturers making up the rest. 2025 is the largest year on record at $55,810, more than ten times the $486 reported in 2019.
Across 153 payments — averaging $405.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$55K
- Medtronic$3K
- Boston Scientific$2K
- Lundbeck LLC$958
- Acorda Therapeutics, Inc$302
- Eisai Inc.$251
- plus $1K from 13 others
What the payments were for
- Speaking & faculty fees$50,56581%
- Travel & lodging$6,71411%
- Food & beverage$4,5927%
- Education$1780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 63 | $54,644 |
| Medtronic(2 entities) | 31 | $2,957 |
| Boston Scientific | 9 | $1,652 |
| Lundbeck LLC | 2 | $958 |
| Acorda Therapeutics, Inc | 3 | $302 |
| Eisai Inc. | 4 | $251 |
| UCB, Inc. | 11 | $229 |
| AstraZeneca(2 entities) | 7 | $159 |
| Teva Pharmaceuticals USA, Inc. | 4 | $153 |
| Roche Products Limited | 1 | $126 |
| Revance Therapeutics, Inc. | 1 | $121 |
| Merz North America, Inc. | 1 | $120 |
| AbbVie | 2 | $107 |
| MDD US Operations, LLC | 4 | $71 |
| SK Life Science, Inc. | 3 | $62 |
| Jazz Pharmaceuticals Inc. | 3 | $59 |
| Averitas Pharma Inc. | 2 | $40 |
| TG Therapeutics, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$62,050 in reported general payments places this provider in the 85th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 11 | $101,189 |
| Nurtec OdtRimegepant Sulfate | 12 | $11,726 |
| Emgality PenGalcanezumab-Gnlm | 11 | $9,026 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 82 | $2,578 |
| Memantine Hcl | 88 | $2,058 |
| Donepezil Hcl | 178 | $1,475 |
| Gabapentin | 54 | $1,165 |
| Quetiapine Fumarate | 48 | $1,140 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 35 | $507 |
| Ropinirole Hcl | 13 | $466 |
| Primidone | 14 | $439 |
| Methylphenidate Hcl | 11 | $276 |
| Sertraline Hcl | 45 | $168 |
Paid to pharmacies, not to this prescriber.
Other neurology in Cleveland
- Imad NajmCleveland$373K
- Hesham AbboudCleveland$363K
- Robert BermelCleveland$302K
- Eric BaronCleveland$297K
- Robert FoxCleveland$296K
- Aarushi SunejaCleveland$269K
- Mary WillisCleveland$254K
- Benjamin WalterCleveland$210K
- Aasef ShaikhCleveland$186K
- Maryann MaysCleveland$173K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.